Supplemental Table 3 from Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing
Jingquan Jia(Duke Medical Center), Andrew B. Nixon(Duke University), Anuradha Bulusu(Georgia Institute of Technology), Herbert I. Hurwitz(Duke Medical Center), Neal Kaplan(Duke Medical Center), Herbert Pang(Duke University), Andrew Dellinger(Duke University), Haiyan Li(Gansu Agricultural University), Leigh A. Howard(Duke Medical Center), Christel Rushing(Duke University), Eric S. Weiss(University of Pittsburgh)
Cited by 0
Related Papers
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
|Journal of Clinical Oncology|2010|840
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
|Blood|2018|402
Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies
|JNCI Journal of the National Cancer Institute|2017|383